Lead Investigator: Neeraj Narula, McMaster University
Title of Proposal Research: Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY
Vivli Data Request: 5945
Funding Source: None
Potential Conflicts of Interest: Neeraj Narula holds a McMaster University Department of Medicine Internal Career Award. Neeraj Narula has received honoraria from Janssen, AbbVie, Takeda, Pfizer, Merck, Lupin and Ferring.
Summary of the Proposed Research:
There is a need for predictor(s) of mucosal healing in patients with Inflammatory Bowel Disease (IBD), in particular with ulcerative colitis, to improve long-term patient outcomes. This study aims to identify possible early predictor(s) for mucosal healing in ulcerative colitis from the VARSITY trial, data accessed through VIVLI.
The participants include those subjects who participated in the VARSITY TRIAL. This study enrolled 771 people, of whom 769 received at least one dose of treatment, either vedolizumab (383 participants) or adalimumab (386 participants).
The proposed research is a post-hoc review of the VARSITY trial data to identify predictor(s) at baseline and week 14 for achieving mucosal healing at week 52 in the study.
The VARSITY trial was a randomized, double-blind, active-controlled trial with two medication treatment groups (vedolizumab or adalimumab) from July 2015 to January 2019 at 245 sites in 34 countries. Inclusion criteria included patients ages 18 to 85 with moderate to severe active ulcerative colitis. This post-hoc analysis aims to evaluate predictors of mucosal healing at week 52 utilizing data including clinical laboratory test results (i.e. fecal calprotectin, a biomarker measurement of inflammation), and a disease activity index for ulcerative colitis referred to as the Mayo scale that includes endoscopic scores evaluated by physicians utilizing imaging of endoscopic procedures read at a central location and patient reported outcomes (i.e stool frequency and rectal bleeding) from baseline and week 14.
A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis
Study ID: NCT02497469
Sponsor ID: MLN0002-3026